top of page

Phase 1/2 DIPG


SonALAsense is conducting a Phase 1/2 dose-escalation study examining the safety, pharmacokinetics, and preliminary efficacy of ascending drug and energy dose combinations for sonodynamic therapy using SONALA-001 in combination with Exablate 4000 Type 2.0 MR-Guided Focused Ultrasound in subjects with Diffuse Intrinsic Pontine Glioma (DIPG)

For more details regarding the study design, please visit our listing:

This trial is now recruiting, Contact Us to learn more about eligibility.

bottom of page